GeneNews in pact for first personalized medicine center in China

GeneNews (TSX:GEN) has signed a memorandum of understanding with Shanghai Biochip, a leading Chinese engineering center for advanced microarray and gene expression profiling technologies, for a strategic alliance to establish the first Sentinel Centre for Personalized Medicine in China. GeneNews and SBC would jointly establish and manage the Sentinel Centre for Personalized Medicine to co-develop [...]

GeneNews launches ColonSentry in Malaysia

GeneNews (TSX:GEN) has announced the commercial launch of ColonSentry, the world’s first blood-based test to determine a person’s current risk for colorectal cancer, in Malaysia through its GeneNews Diagnostics Sdn. Bhd. subsidiary. “We are excited that GeneNews Diagnostics will now be able to provide the Malaysian population with access to this potentially life-saving colorectal cancer [...]

Neoprobe to unveil new brand identity

Neoprobe (NASDAQ:NEOP) expects to announce in the coming weeks a new brand identity to mark a “formal turning point in the recognition of Neoprobe as a precision diagnostics company focused on the radiopharmaceutical space,” CEO Dr. Mark Pykett said in the quarterly report. During the third quarter, the company its GDS line of gamma detection [...]

Schizophrenia biomarkers found by GeneNews’ Sentinel Principle

A study using GeneNews’ (TSX:GEN) Sentinel Principle platform technology to identify complex changes in blood gene expression patterns that may be indicative of underlying risk factors for schizophrenia will be published in the American Journal of Medical Genetics Part B and is currently available online. “This study shows that we can identify a gene signature [...]

Rodman sees potential approval of ColonSentry in fourth quarter

In a meeting last week at the Rodman & Renshaw conference with Enzo Biochem (NYSE:ENZ), analyst Yigal Nochomovitz came away with an impression that feedback from New York State regulators “has been favorable” for Enzo’s bid to obtain approval for the GeneNews (TSX:GEN) ColonSentry molecular diagnostic test for assessing a patient’s current risk of having [...]

Neoprobe gets positive scientific advice from EMA for RIGScan CR

Neoprobe (AMEX:NEOP) received positive scientific advice late last week from the European Medicines Agency (EMA) on the development of RIGScan CR, its proprietary radiopharmaceutical for the detection of colorectal cancer. Among other things, the European regulatory body confirmed the opportunity for Neoprobe to consider evaluating a humanized RIGScan antibody for clinical development and commercialization. The [...]

GeneNews technology able to predict risk of liver cancer for patients with chronic hepatitis

A poster entitled “Biomarkers to predict risk of subsequent hepatocellular cancer in patients with chronic hepatitis,” describing the initial phase of analysis of a 1,600-cohort study using GeneNews’ (TSX:GEN) Sentinel Principle, was presented at the 9th Liver Update 2011 conference in Malaysia. The poster reports on the application of the Sentinel Principle platform technology to [...]

JAMA lymph node study heightens visibility of Neoprobe

  A groundbreaking lymph node study published in The Journal of the American Medical Association last month has turned the spotlight on Neoprobe (AMEX:NEOP) and its lymphatic tissue tracing agent, Lymphoseek. The study described how a routine procedure for the treatment of early breast cancer – the surgical removal of cancerous lymph nodes from the [...]

GeneNews gets Malaysian seed grant

GeneNews (TSX:GEN) has received approval of a seed capital grant of about $625,000 from the Malaysian Biotechnology Corp. to support the commercial launch of its ColonSentry, the world’s first blood-based test to determine a person’s current risk for colorectal cancer, in Malaysia. “Driving the global commercialization and clinical adoption of the ColonSentry test as an [...]

GeneNews partner readying ColonSentry submission

Enzo Biochem’s (NYSE:ENZ) clinical labs division has completed validation testing of the GeneNews (TSX:GEN) ColonSentry pre-screening test for colorectal cancer and is in the final stages of submitting the data package to New York State regulatory authorities, according to a new report by Rodman & Renshaw. Analyst Reni Benjamin writes that the validation “demonstrated consistency [...]

Next Page »